Skip Navigation

European Heart Journal 1986 7(2):165-170;
Copyright © 1986 by the European Society of Cardiology.
This Article
Right arrow Full Text (PDF)
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by CORBIN, D. O. C.
Right arrow Articles by HOUSLEY, E.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by CORBIN, D. O. C.
Right arrow Articles by HOUSLEY, E.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© 1986 The European Society of Cardiology

A randomized double blind cross-over trial of nifedipine in the treatment of primary Raynaud's phenomenon

D. O. C. CORBIN, D. A. WOOD, C. C. A. MACINTYRE and E. HOUSLEY

Peripheral Vascular Clinic, Royal Infirmary Edinburgh, U.K.

Received 5 June 1985; revised 23 September 1985; .

Address for correspondence: Dr E. Housley, Peripheral Vascular Clinic, Royal Infirmary, Edinburgh EH3 9YW, UK

Abstract

During three winter months, 23 women participated in a double blind placebo controlled cross-over clinical trial of nifedipine in the treatment of Raynaud's phenomenon. Nifedipine and placebo were given in random order for two consecutive four-week periods. The dose of nifedipine was increased from 5 mg three times daily (ids) to 15 mg tds. During the final two weeks, the median number of attacks of Raynaud's phenomenon on nifedipine was 2–3 per week compared to 5.0 on placebo (P < 0.01). Fifteen patients gave nifedipine a higher drug evaluation score than placebo (P < 0.01). Side-effects were experienced by 14 patients (61%) on nifedipine and by two on placebo (P = 0.005). Finger systolic pressure after digit cooling did not differ significantly at the end of each treatment period. Nifedipine is effective in primary Raynaud's phenomenon in most patients but side effects are common.

Key Words: Raynaud's phenomenon • nifedipine • calcium entry blockers • digit cooling • finger systolic pressure • vasodilators


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Rheumatology (Oxford)Home page
A. E. Thompson and J. E. Pope
Calcium channel blockers for primary Raynaud's phenomenon: a meta-analysis
Rheumatology, February 1, 2005; 44(2): 145 - 150.
[Abstract] [Full Text] [PDF]

Home page
 Arch Intern MedHome page
Raynaud's Treatment Study Investigators
Comparison of Sustained-Release Nifedipine and Temperature Biofeedback for Treatment of Primary Raynaud Phenomenon: Results From a Randomized Clinical Trial With 1-Year Follow-up
Arch Intern Med, April 24, 2000; 160(8): 1101 - 1108.
[Abstract] [Full Text] [PDF]

Home page
 ANN INTERN MEDHome page
D. B. Badesch, V. F. Tapson, M. D. McGoon, B. H. Brundage, L. J. Rubin, F. M. Wigley, S. Rich, R. J. Barst, P. S. Barrett, K. M. Kral, et al.
Continuous Intravenous Epoprostenol for Pulmonary Hypertension Due to the Scleroderma Spectrum of Disease: A Randomized, Controlled Trial
Ann Intern Med, March 21, 2000; 132(6): 425 - 434.
[Abstract] [Full Text] [PDF]

Home page
 ANGIOLOGYHome page
V.F. Challenor, D.G. Waller, R.A. Hayward, M.J. Griffin, and O.S. Roath
Vibrotactile Sensation and Response to Nifedipine Dose Titration in Primary Raynaud's Phenomenon
Angiology, February 1, 1989; 40(2): 122 - 128.
[Abstract] [PDF]

Home page
 ANGIOLOGYHome page
A. Kahan, B. Amor, C. J. Menkes, S. Weber, F. Guerin, and M. Degeorges
Nicardipine in the Treatment of Raynaud's Phenomenon: A Randomized Double-Blind Trial
Angiology, April 1, 1987; 38(4): 333 - 337.
[Abstract] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.